Pioneers at Children's Hospital of Philadelphia greet European Commission's approval of Kymriah

(Children's Hospital of Philadelphia) Oncologists from Children's Hospital of Philadelphia today celebrated a watershed moment in medicine: approval by the European Commission of Kymriah (tisagenlecleucel, formerly CTL019) -- the first-ever US Food and Drug Administration (FDA) approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers, pioneered together with Novartis and the Perelman School of Medicine at the University of Pennsylvania.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news